Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches

出版年份 2017 全文链接

标题

作者

关键词

Immunotherapy, Pembrolizumab, Nivolumab, First-line, Non-small cell lung cancer

出版物

Volume 106, Issue -, Pages 70-75

出版商

Elsevier BV

发表日期

2017-02-06

DOI

10.1016/j.lungcan.2017.02.002

联系作者

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started